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Neurobehavioral consequences of chronic
intrauterine opioid exposure in infants and
preschool children: a systematic review and
meta-analysis
Alex Baldacchino1*, Kathleen Arbuckle2, Dennis J Petrie3 and Colin McCowan4
Abstract
Background: It is assumed within the accumulated literature that children born of pregnant opioid dependent
mothers have impaired neurobehavioral function as a consequence of chronic intrauterine opioid use.
Methods: Quantitative and systematic review of the literature on the consequences of chronic maternal opioid use
during pregnancy on neurobehavioral function of children was conducted using the Meta-analysis of Observational
Studies in Epidemiology (MOOSE) and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis
(PRISMA) guidelines. We searched Cinahl, EMBASE, PsychINFO and MEDLINE between the periods of January 1995
to January 2012.
Results: There were only 5 studies out of the 200 identified that quantitatively reported on neurobehavioral
function of children after maternal opioid use during pregnancy. All 5 were case control studies with the number of
exposed subjects within the studies ranging from 33–143 and 45–85 for the controls. This meta-analysis showed no
significant impairments, at a non-conservative significance level of p < 0.05, for cognitive, psychomotor or observed
behavioural outcomes for chronic intra-uterine exposed infants and pre-school children compared to non-exposed
infants and children. However, all domains suggested a trend to poor outcomes in infants/children of opioid using
mothers. The magnitude of all possible effects was small according to Cohen’s benchmark criteria.
Conclusions: Chronic intra-uterine opioid exposed infants and pre-school children experienced no significant
impairment in neurobehavioral outcomes when compared to non-exposed peers, although in all domains there
was a trend to poorer outcomes. The findings of this review are limited by the small number of studies analysed,
the heterogenous populations and small numbers within the individual studies. Longitudinal studies are needed
to determine if any neuropsychological impairments appear after the age of 5 years and to help investigate further
the role of environmental risk factors on the effect of ‘core’ phenotypes.
Keywords: Neuropsychology, Psychomotor, Cognition, Methadone, Opioids, Meta-analysis
Background
Substance abuse has been a global problem for many de-
cades and in recent years there has been a significant in-
crease in the numbers of people using opioids [1].
Opioid use was seen as a predominately male problem
but today there are many women using opioids which
could lead to an increase in problem pregnancies [2].
During pregnancy drugs will cross the placenta and can
have an effect on the foetus. This effect is often hard to
quantify as there are other aspects that could be consid-
ered as having a larger effect on child outcomes, for ex-
ample, the quality of care or the environment [3]. Many
studies examining the impact of opioid use during preg-
nancy on child outcomes have concentrated on treat-
ment populations (methadone and/or buprenorphine)
for recruitment as this group is easier to reach than
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heroin users [4]. Research has attempted to address birth
problems, neonatal abstinence syndrome, mortality and
co-morbidities as well as neuro-developmental issues in
children sometimes with conflicting results [5]. There are
many reports into neonatal abstinence syndrome and birth
parameters but fewer reports on neuro-developmental
issues surrounding prenatal exposure to opioids [6-10].
In the U.K. it is estimated that around 280,000 people
use opioids and that around 30% are women [11,12]. In
2009/2010 925 pregnancies in Scotland reported drug
misuse, a rate of 16.1 per 1,000 pregnancies, with opi-
oids reported in 506 (55%) of these pregnancies [2].
Over half the pregnant mothers who report drug use are
opioid dependent with consequential increase in risk to
both mother and expected child.
Replacement prescribing with methadone and recently
buprenorphine forms the main plank of medical treatment
for opioid dependency in the United Kingdom, reflecting a
comprehensive and evolving evidence base which consis-
tently demonstrates the effectiveness of methadone in
delivering positive outcomes in a complex and demanding
population [13-15]. Properly prescribed and adequately
supported, methadone prescribing achieves harm reduc-
tion outcomes in opioid dependent patients [16,17]. It is
also associated with reduced mortality and improved qua-
lity of life [18]. The duration and dosage of methadone
was also closely observed to be relevant factors in treat-
ment outcomes with longer duration and higher dosages
showing positive outcomes [19-21].
In contrast, some neuropsychological studies of chronic
methadone users have identified deficits in executive func-
tion measures. These have included impairments in cogni-
tive flexibility [22,23], in strategic planning [24,25] and
decision making [26]. Other studies found no clear deficits
when comparing the performance of healthy controls,
with that of opioid abstinent or methadone users [27,28].
The accumulated literature tends to assume that neuro-
psychological function is commonly impaired as a conse-
quence of chronic methadone use justifying an abstinence
agenda with premature termination of methadone treat-
ment [29]. Furthermore a recent meta-analysis on the
neuropsychology of chronic opioid use suggested impair-
ment in verbal working memory, cognitive impulsivity
(risk taking) and cognitive flexibility (verbal fluency) with
a medium effect size [30].
An early study has suggested that methadone-exposed
children have better birth outcomes compared to heroin-
exposed children, suggesting that opioid treatment during
pregnancy is beneficial for the neonate [31]. Despite
evidence of the beneficial effects of methadone in the care
of pregnant opioid-dependent women, approximately half
of all infants prenatally exposed to methadone require
medical treatment for neonatal abstinence syndrome
[32]. Accordingly, there are risks associated with prenatal
exposure to methadone or buprenorphine [33]. A recent
Cochrane systematic review identified four trials compa-
ring methadone in pregnancy with buprenorphine in three
studies and oral slow-release morphine in the other [34].
Patients using methadone had lower dropout rates than
for the other treatment options but there were no dif-
ferences in neo-natal abstinence syndrome in the trials.
Infant birth weight was higher for buprenorphine users
in two trials but no different in the other two trials.
Women on slow-release morphine were less likely to
also use heroin in the third trimester than methadone
users. The authors highlighted the lack of available evi-
dence to inform treatment decisions for pregnant women
with opioid dependence.
The literature pertaining to the long-term develop-
mental effects of prenatal methadone and buprenor-
phine exposure is relatively sparse and contradictory [5].
While some studies report no long-term effects [35-37]
others report reduced performance on tests of cognitive
development [38-41].
While this literature, together with the neurobeha-
vioral effects of intrauterine opioid use on children, has
been reviewed by Konijnenberg and Melinder (2011) [5],
Whitham (2012) [42] and Hutchings (1987) [43], tra-
ditional narrative reviews typically assume statistically
significant group differences to be evidence for cognitive
and/or psychomotor impairment, without giving due
consideration to the magnitude of such differences by
reporting effect sizes.
This paper will determine the strength and consistency
of neurobehavioral impairment in cognitive and psycho-
motor function in opioid exposed infants and pre-school
children when compared to healthy non-opioid exposed
controls by performing a systematic literature review
and consequently quantitatively synthesising the existing
literature using meta-analytic methodology [44,45].
Method
Inclusion and exclusion criteria
The systematic review of the literature was conducted
accordingly to the Meta-analysis of Observational Stu-
dies in Epidemiology (MOOSE) guidelines [46] and the
Preferred Reporting Items for Systematic reviews and
Meta-Analysis (PRISMA) guidelines [47].
For the purpose of this review, the meanings of the
terms ‘opioid’ and ‘opiate’ were considered as largely
synonymous, with opioid being used, as it has a broader
definition. An Infant was defined as a child up to 2 years
old, pre-school child as one between 3 and 5 years of
age and a school child as one between 6 and 12 years
of age. Neurobehavioral function was defined as ‘growth
of perceptual, emotional, intellectual, and behavioural
capabilities and functioning during childhood (prior
to puberty) which includes development of language,
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symbolic thought, logic, memory, emotional awareness,
empathy, a moral sense, and a sense of identity, inclu-
ding sex-role identity’ [48].
Only studies that recruited opioid users were included
in the meta-analysis. Furthermore all trial methodologies,
not only RCTs, were considered. Studies had to use a vali-
dated diagnostic system and explicitly define whether their
participants were opioid/methadone dependent [49,50].
We excluded studies that recruited mothers who were
polydrug users during term pregnancy even though they
might have also been taking opioids. Studies that only
investigated the immediate effects of opioid use on neo-
nates including neonatal abstinence syndrome and the
neurological consequences of opioid exposure were also
excluded. Sufficient study statistics not convertible to ef-
fect size (d) e.g. means, standard deviation, F, t, X 18
were also excluded, as well as studies with less than 15
in the total sample size.
Search strategy
Articles were identified using an electronic and hand
strategy based search. A computer based search was per-
formed using the following database: Cinahl, EMBASE,
PsychINFO and MEDLINE between the periods of
January 1995 to January 2012 (17 years). No language con-
straints were applied. Subject headings originally included
‘child, opioid, prenatal exposure and substance misuse’.
(Refer to Additional file 1: Table S1)
This was followed with the term ‘neurobehavioral’
which was subsequently replaced with a succession of
terms describing names of a list of cognitive and psycho-
motor tests and using wild cards.
Two of the authors (AB and KA) independently reviewed
all the identified abstracts from the electronic search, se-
lected studies and published reviews. A snowballing tech-
nique was employed so that the reference list of the
identified articles was screened to find other suitable stu-
dies. The literature search was further enhanced by hand
searching 22 journals for the last 5 years (2008–2012). They
include Drug and Alcohol Dependence, Addictive Beha-
viours, Addiction, European Addiction Research, Journal
of Substance Abuse Treatment, Child Neuropsychology,
Neurotoxicology, Neurotoxicology and Teratology, Toxicology
Letters, Psychological Medicine, European Journal of Paedi-
atrics, Paediatrics, Developmental and Behavioral Paediat-
rics, Archives of Diseases in Childhood, Paediatric Research,
NeuroImage, Early Human Development, Women and
Birth, Obstetrics, British Journal of Gyneacology and Obstet-
rics, British Medical Journal, Neuroscience and Biobeha-
vioral Reviews.
Data analysis and study detail
Standard meta-analytic techniques were employed to
this review [51]. Magnitude is indexed with the effect
size d that is meant to reflect the degree to which the
dependent variable is present in the sample group or the
degree to which the null hypothesis is false [52]. In
mathematical terms d is the difference between two
group means standardised via pooled standard deviation
units. Effect sizes (i.e. Cohen’s d statistics) were calcu-
lated for each neurobehavioral test and then adjusted for
sampling bias [53]. A value of 0.80 is regarded as a large
effect size, 0.5 as a medium effect and 0.2 small [54,55].
Formulae were appropriately adjusted so that all derived
statistics informally represented the same direction; that
is the same polarity of performance when comparing
groups. Negative scores always represented worse per-
formance on the part of the opiate exposed group.
The multi-domain model is the most widely used model
of infant-pre-school assessment. The theoretical basis of
the model is that the Child Development is an inter-
actively unfolding, continuous process that occurs in se-
veral distinct but interrelated domains. Traditionally these
domains include (a) motor (fine and gross motor skills),
(b) communication (receptive and expressive language),
(c) cognition (problem solving skills), (d) adaptive compe-
tence (dressing, eating, toileting), and (e) personal-social
competence [56,57]. For this review all relevant test vari-
ables were coded into one of three neurobehavioral
domains [56,58].
1. Cognitive
2. Psychomotor
3. Behavioural observations
In keeping with recommendations on meta-analytical
research in neuropsychology, previous factor-analysis,
where possible, informed the placement of measures into
the aforementioned domains. This approach provides an
objective alternative to the arbitrary grouping of neuro-
psychological variables on the basis of face validity or un-
confirmed notions held within the existing literature [59].
Unfortunately the factor-analytical studies to date do not
encompass all of the neuropsychological measures that
were encountered in this comprehensive systematic re-
view. To this end, there was also a reliance on authorita-
tive texts and discussion with experts in the field of
neuropsychology and/or cognitive measures to help or-
ganise remaining measures [57,60] and, when necessary,
we relied on the classification used by the authors of a
given study [5,42,43] (Table 1).
To meet the assumption of independence, when mul-
tiple test variables in a study contributed to any one
neuropsychological domain, the effect size for each meas-
ure was assessed separately and then the mean effect size
of these measures were combined to assess the overall
outcome in the respective area of functioning. Multiple
measurements can increase the likelihood of Type 1 errors
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Table 1 Neurobehavioral functions
Main domain Definition Tests
General cognitive Child’s ability to learn and solve problems WPPSI-R, DAS, SBIS, MSCA,MSEL, GDS, BSID
Language Child’s ability to both understand and use language PPVT-III, NEPSY, RDLS, GDS
Non verbal processing Child’s ability to organize the visual-spatial field, adapt
to new or novel situations, and/or accurately read
nonverbal signals and cues.
K-ABC, Non verbal subtests of DAS, WPPSI, MSCA
Psychomotor The child’s ability to connect thoughts with muscle movements Vineland Motor Domain, MSCA, NEPSY, GDS, BSID
Executive functions Child’s ability to analyze situations, plan and take action,
focus and maintain attention, and adjust actions as needed
to get the job done
WPPSI-R Animal Pegs, NEPSY, GDS
Memory Child’s ability to hold and manipulate information over brief
periods of time, in the course of ongoing cognitive activities
DAS, MSCA, BSID, NEPSY
Social/emotional adjustment Child’s ability to interact with others, including helping
themselves and self-control.
VSS, CBC, CBRS, GDS, IBR, RPD-Q, VSMS
BSID, Bayley Scales of Infant Development Test (Motor and Cognitive); CBRS, Conners’ Behavior Rating Scale; CBC, Achenbach Child Behavior Checklist; DAS, Differential
Ability Scale-Preschool Core; GDS, Griffiths Developmental Scale; IBR, Bayley’s Infant Behaviour Record; K-ABC, Kaufman Assessment Battery for Children; MCSA, McCarthy
Scales of Children’s Abilities; MSEL, Mullen Scales of Early Learning; NEPSY, Developmental NEuroPSYchological Assessment; PPVT-III, Peabody Picture Vocabulary Test-3rd
Edition; RPD-Q, Rapid Pre-screening Denver Questionnaire; RDLS, Reynell Developmental Language Scale; SBIS, Stanford-Binet Intelligence Scale; VSS, Vineland Social-Emotional
Early Childhood Scales; VSMS, Vineland Social Maturity Scale; WPPSI-R, Weschler Preschool and Primary Scale of intelligence-Revised.
Figure 1 Neurobehavioral consequences of chronic opioid intrauterine exposure in infants, preschool and school children: QUality Of
Reporting Of Meta-analysis (QUOROM).
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and so a p value over 0.01 will be interpreted with caution
even though analysis will use a significant level of p < 0.05.
Tests for the presence and degree of heterogeneity were
conducted using the Q statistic [55] and I2 index [61] re-
spectively. However, quantification of heterogeneity is only
one component of a wider investigation of variability
across studies, the most important being diversity in cli-
nical and methodological domains, and the observed de-
gree of inconsistency across studies with regards to the
direction of effects [62]. As different scales were some-
times used by different studies, standardised mean dif-
ference (SMD) effect-size estimates were calculated. In
case of significant heterogeneity, random effect models
were applied [63,64].
Research with statistically significant results are poten-
tially more likely to be submitted and published than
studies with non-significant results. The presence of
such publication bias was assessed informally by visual
inspection of funnel plots and formally by its statistical
analogue, Fail Safe N, according to Orwin [65].
A Fail-Safe N is the number of non significant, unpub-
lished, or missing studies that would need to be added to
the meta-analysis in order to change the overall result
from significance to non-significance. More than two
studies are needed to enable a Fail-Safe N to be calculated.
Eligible research studies comprising a common dependent
variable as well as statistics that can be transformed
into effect sizes were systematically surveyed. Individual
study results (typically means and standard deviations
from each group) and relevant moderator variables con-
sidered as relevant by previous reviews (e.g. dosage of
maternal methadone during pregnancy, gestational age,
presence of Neonatal Abstinence Syndrome (NAS), qua-
lity of the study, and population studied) were used as
moderators if needed during this review. They were ab-
stracted, quantified,coded and assembled into a database
and analysed using Comprehensive Meta-Analysis Version
2 [66]. The significance level was p = 0.01 and in Q statis-
tics p = 0.10.
Assessment of study quality
For all review questions, data were extracted by one re-
viewer and checked by another. Discrepancies were re-
solved by referral to the original studies and, if necessary,
arbitration done by a third reviewer. Duplicate publica-
tions were actively screened for and, when found, the lat-
est and most complete report was used. The Effective
Public Health Practice Project (EPHPP) quality assessment
checklist (amended) was used in this study [67]. For prag-
matic reasons no papers were excluded on quality grounds
Table 2 General characteristics of selected studies comparing opioid exposed infants and children with non opioid
exposed controls (n = 5)
Study Age in months
when tested
Number Country Type of opioid
exposure
Socio-economic status Measures used
(Neurobehavioral)
Infants
Hunt et al. [6] 19.9 79OE Australia Illicit heroin n/a VSMS, MSCA, BSID
61C
Moe et al. [71] 12 64OE Norway Illicit heroin 3.9OE*1 v 4.1C MSCA, BSID
52C
Hans et al. [74] 12/24 33OE USA Illicit heroin 5*2 BSID, IBR
45C Prescribed methadone
Bunikowski et al. [73] 12.4 42OE Germany Illicit heroin 4OE*3 v 6C GDS, RPD-Q
47C Prescribed methadone
Pre-school children
Hunt et al. [6] 38.2 67OE Australia Illicit heroin n/a BSID, MSCA
44C
Moe et al. [71] 54 64OE Norway Illicit heroin 3.9OE*1 v 4.1C BSID, MSCA
52C
Ornoy et al. [72] 60 93OE Israel Illicit heroin 3.9OE*3 BSID, MCSA, Achenbach CBC
50EC 2.4C
85C
OE, Opioid Exposed; EC, Environmental Controls; C, Controls; *1, SES or mean value of both parent education and occupation; *2, Hollinghead level; *3, Socio-status; n/
a, not available. Achenbach CBC, Achenbach Child Behavior Checklist (Externalising including attention); BSID, Bayley Scales of Infant Development Test (Psychomotor
and Mental Scores); GDS, Griffiths Developmental Scale (Locomotor); IBR, Bayley’s Infant Behaviour Record; MCSA, McCarthy Scales of Children’s Abilities (Motor scale);
RPD-Q, Rapid Pre-screening Denver Questionnaire; VSMS, Vineland Social Maturity Scale.
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as all papers were weak to moderate (Refer to Additional
file 2: Table S2).
Ethical approval and informed patient consent was not
required as this study was a literature review and had no
direct patient contact or influence on patient care.
Results
Studies selected and population studied
Combined searches yielded 1452 references. In total 65 ar-
ticles were retrieved for further assessment from which 65
studies identified intrauterine exposure to opioids and
reported health and developmental outcomes for the
opioid exposed children. From these studies, 8 articles
were found to investigate the cognitive, psychomotor and
behavioral outcomes in opioid exposed infants, pre-school
and school children when compared to healthy non-
opioid exposed controls. Only 5 studies could be further
utilised in this meta-analysis since 1 study measured motor
rather than psychomotor skills [68] and 2 other studies had
small sample sizes of < 15 [69,70].
Furthermore 2 studies tested the same cohort during in-
fancy and pre-school periods [6,71] and another study
tested the cohort during pre-school and school periods
[72]. Considering that only one study measured outcomes
during the school period [72] it was decided that further
analysis should concentrate on the infancy and pre-school
periods. During these periods there were 4 studies com-
paring opioid exposed infants with controls [6,71,73,74]
and 3 studies comparing opioid exposed pre-school chil-
dren with controls [6,71,72]. In Hans et al. [74] infants in
the cohort were tested at 1 and 2 years old allowing two
observational points (Figure 1).
All studies were case controlled observational studies
conducted with a population living in urbanised and low
socioeconomic communities exposed to either heroin or
methadone.
Table 3 Specific characteristics of selected studies comparing opioid exposed infants and children with non opioid
exposed controls (n = 5)
Study Age in months
when tested
Gestational age
in weeks
Mean birth
weight in g
Mean head
circumference (cms)
Mother’s age
(median) in years
Mother’s methadone
dose in mg
Infants
Hunt et al. [6] 19.9 37.7 2900in OE 33.6 in OE n/a n/a
3300 in C 34.5 in C
Moe et al. [71] 12 n/a 3037 in OE 34 in OE n/a na
3754 in C 35.8 in C
Hans et al. (2011) 12/24 n/a 2922 in OE n/a 27.1 in OE 20 mg
3236 in C 25.8 in C
Bunkowski et al. (1998) 12.4 37.4 2783 in OE n/a 27 in OE n/a
3240 in C 30.2 in C
Pre-school children
Hunt et al. [6] 38.2 37.7 2900in OE 33.6 in OE n/a n/a
3300 in C 34.5 in C
Moe et al. [71] 54 n/a 3037 in OE 34 in OE n/a n/a
3754 in C 35.8 in C
Ornoy et al. [72] 60 36 2487 in OE 27.8 in OE n/a n/a
3346 in C 39.8 in C
Mg, Milligrammes; g, Grammes; cms, Centimetres; n/a, Not available; OE, Opioid Exposed; C, Non-Opioid Exposed Controls.
Study name Subgroup within study Outcome Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Hunt et al (2008) 1.5 years old BSID (Mental) 0.183 0.324 0.105 -0.452 0.818 0.565 0.572
Bunkowski et al (1998)1 year old GDS  (DQ) 0.047 0.407 0.166 -0.750 0.845 0.116 0.907
Moe et al (2002) 1 year old BSID (Mental) 0.127 0.419 0.176 -0.695 0.949 0.303 0.762
Hans et al (2001) 1 year old BSID (Mental 0.713 0.390 0.152 -0.051 1.477 1.829 0.067
Hans et al  (2001) 2 years old BSID (Mental) 0.128 0.400 0.160 -0.657 0.913 0.319 0.750
0.242 0.171 0.029 -0.094 0.578 1.412 0.158
-2.00 -1.00 0.00 1.00 2.00
Fav ours opioid exposed infants Fav ours non-opioid exposed infants
Figure 2 Forrest plots comparing cognition in opiod and non-opiod exposure.
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The global quality assessment reported four studies as
of moderate quality and one as weak. The assessment
for analysis performed was moderate for all studies but
all other domains were reported as either weak or mo-
derate (see Additional file 2: Table S2).
Cohort characteristics for the 4 studies comparing opi-
oid exposed infants with controls describe a total num-
ber of 218 individuals tested compared to a total of 205
non opioid exposed controls. The mean infant age was
14.1 months (1.2 years). Cohort characteristics for the 3
studies comparing opioid exposed pre-school children
with non opioid exposed controls describe a total num-
ber of 224 individuals tested compared to a total of
231 non opioid exposed controls. The mean age of the
pre-school children tested was 50.7 months (4.2 years).
General and specific characteristics of the included stu-
dies are shown on Tables 2&3.
Neurobehavioral function
There were six effect size measures possible (3 for the
infant cohort and 3 for the pre-school cohort groups)
from the selected studies. There were no effect sizes
identified as greater than 2× inter-quartile range (25 and
75 percentile) from the nearest quartile (outliers) [75].
Opioid exposed infants compared with non-opioid exposed
infants
For cognition: a total of four studies were pooled including
251 opioid exposed and 315 non-opioid exposed infants.
Pooling of the four studies revealed a non significant effect
size of 0.24 in favour of non-opioid exposed controls.
(Z = 1.41, p = 0.16). The Q and I2 statistics, showed no
significant evidence of heterogeneity with the use of a
fixed effects model (Q = 1.88, p < 0.76, I2 = 0.00). Lastly
the 95% confidence interval did contain zero and, hence
the null hypothesis that the effect size was not different
from zero could not be rejected (95% CI; −0.09, 0.58)
(Figure 2).
For psychomotor: a total of four studies were pooled
including 251 opioid exposed and 315 non-opioid ex-
posed infants. Pooling of the four studies revealed a non
significant effect size of 0.28 in favour of non-opioid ex-
posed controls. (Z = 1.67, p = 0.09).The Q and I2 statis-
tics, showed no significant evidence of heterogeneity
with the use of a fixed effects model (Q = 3.98, p < 0.41,
I2 = 0.00). Lastly the 95% confidence interval did contain
zero and, hence the null hypothesis that the effect size
was not different from zero could not be rejected
(95% CI; −0.05, 0.61) (Figure 3).
For behaviour: a total of three studies were pooled in-
cluding 145 opioid exposed and 216 non-opioid exposed
infants. Pooling of the three studies revealed a non sig-
nificant effect size of 0.40 in favour of non-opioid
exposed controls. (Z = 1.25, p = 0.20). The Q and I2 sta-
tistics, however showed significant evidence of hetero-
geneity with the use of a fixed effects model (Q = 7.13,
p < 0.03, I2 = 71.93). As a result an additional analysis
was performed that corrected for random effects. The
corrected mean effect size changed to 1.21 and a non-
significant Z score (Z = 1.30, p = 0.19). Lastly the 95%
confidence interval did contain zero and, hence the
null hypothesis that the effect size was not different
from zero could not be rejected (95% CI; −0.61, 3.03)
(Figure 4).
Study name Subgroup within study Outcome Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Hunt et al (2008) 1.5 years old BSID (Psychomotor) 0.165 0.358 0.128 -0.536 0.867 0.462 0.644
Bunkowski et al (1998) 1 year old GDS  (Locomotor) 0.047 0.363 0.132 -0.665 0.758 0.129 0.897
Moe et al (2002) 1 year old BSID (Psychomotor) 0.139 0.399 0.159 -0.643 0.922 0.349 0.727
Hans et al (2001) 1 year old BSID (Psychomotor) 0.950 0.378 0.143 0.210 1.691 2.515 0.012
Hans et al  (2001) 2 years old BSID (Psychomotor) 0.115 0.371 0.138 -0.612 0.843 0.310 0.756
0.279 0.167 0.028 -0.048 0.605 1.670 0.095
-2.00 -1.00 0.00 1.00 2.00
Fav ours opioid exposed infants Fav ours non-opioid exposed infants
Figure 3 Forrest plots comparing psychomotor in opiod and non-opiod exposure.
Model Study name Subgroup within study Outcome Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Hunt et al (2008) 1.5 years old Vineland Social Maturity Scale (VSMS) 0.155 0.349 0.122 -0.529 0.838 0.443 0.658
Hans et al (2002) 1 year old Infant Behaviour Record (IBR) Attention 4.464 1.593 2.539 1.341 7.587 2.801 0.005
Hans et al  (2001) 2 years old Infant Bahaviour Record (IBR) Attention 0.711 0.876 0.768 -1.006 2.428 0.811 0.417
Fixed 0.399 0.318 0.101 -0.224 1.021 1.256 0.209
-4.00 -2.00 0.00 2.00 4.00
Favours opioid exposed ipre-school infants Favours non-opioid exposed pre-school infants
Figure 4 Forrest plots comparing behaviour in opiod and non-opiod exposure.
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Opioid exposed pre-school children compared with
non-opioid exposed pre-school children
For cognition: a total of three studies were pooled in-
cluding 224 opioid exposed and 181 non-opioid exposed
pre-school children. Pooling of the three studies revealed
a non significant effect size of 0.18 in favour of non-
opioid exposed controls. (Z = 0.75, p = 0.46).The Q and
I2 statistics, showed no significant evidence of hetero-
geneity with the use of a fixed effects model (Q = 0.38,
p < 0.83, I2 = 0.00). Lastly the 95% confidence interval
did contain zero and, hence the null hypothesis that the
effect size was not different from zero could not be
rejected (95% CI; −0.30, 0.67) (Figure 5).
For psychomotor: a total of three studies were pooled
including 224 opioid exposed and 181 non-opioid ex-
posed pre-school children. Pooling of the three studies
revealed a non significant effect size of 0.28 in favour of
non-opioid exposed controls. (Z = 1.00, p = 0.32).The Q
and I2 statistics, showed no significant evidence of he-
terogeneity with the use of a fixed effects model (Q =
0.18, p < 0.91, I2 = 0.00). Lastly the 95% confidence inter-
val did contain zero and, hence the null hypothesis that
the effect size was not different from zero could not
be rejected (95% CI;-0.27, 0.82) (Figure 6).
For behaviour: a total of two studies were pooled inclu-
ding 160 opioid exposed and 129 non-opioid exposed pre-
school children. Pooling of the two studies revealed a non
significant effect size of 0.38 in favour of non-opioid
exposed controls. (Z = 1.30, p = 0.19). The Q and I2 statis-
tics, showed no significant evidence of heterogeneity with
the use of a fixed effects model (Q = 0.02, p < 0.89,
I2 = 0.00). Lastly the 95% confidence interval did contain
zero and, hence the null hypothesis that the effect size was
not different from zero could not be rejected (95%
CI;-0.25, 1.25) (Figure 7).
Discussion
Key findings
In this first ever quantitative review of the research li-
terature on the neurobehavioral outcomes as a result of
intra-uterine opioid exposure in infants and pre-school
children the meta-analysis has determined what abilities,
if any, were reliably found impaired across studies when
compared with non-opioid exposed controls. Our findings
indicate no significant impairments in cognitive, psycho-
motor or observed behavioural outcomes for chronic intra-
uterine exposed infants and pre-school children, although
in all domains there is a trend to poor outcomes in infants/
children of opioid using mothers (Table 4).
The result of this systematic review is in accordance
with Whitham [42] who conducted an open label non
randomised flexible dosing longitudinal study with re-
sults showing that children prenatally exposed to illicit
heroin and/or methadone did not differ to non-exposed
infants and other children in cognitive, psychomotor
and caregiver rated temperament outcomes. As a recent
review observed, the conflicting results of traditional sys-
tematic reviews on this subject could be that most chil-
dren in these studies were exposed to other drugs in
addition to opioids such as methadone [5]. Another
explanation given to the conflicting results may be
that various studies were conducted using different
Study name Subgroup within study Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Hunt et al (2008) 3 years old McCarthy 0.445 0.491 0.241 -0.518 1.408 0.906 0.365
Ornoy et al (2001/2003) 5 years old McCarthy 0.078 0.423 0.179 -0.752 0.907 0.184 0.854
Moe et al (2002) 4.5 years old McCarthy 0.111 0.385 0.148 -0.644 0.866 0.288 0.773
Walhord et al (2007) 4.5 years old McCarthy 0.000 0.414 0.172 -0.812 0.812 0.000 1.000
0.136 0.212 0.045 -0.279 0.551 0.641 0.521
-2.00 -1.00 0.00 1.00 2.00
Favours opioid exposed pre-school children Favours non-opioid exposed pre-school children
Figure 5 Forrest plots comparing cognition in opiod and non-opiod exposure.
Study name Subgroup within study Outcome Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Hunt et al (2008) 3 years old McCarthy Motor Scale 0.445 0.491 0.241 -0.518 1.408 0.906 0.365
Ornoy et al (2001/2003) 5 years old McCarthy Motor Scale 0.162 0.494 0.244 -0.806 1.130 0.328 0.743
Moe et al (2002) 4.5 years old McCarthy Motor Scale 0.228 0.459 0.211 -0.672 1.127 0.496 0.620
Walhord et al (2007) 4.5 years old McCarthy Motor Scale 0.000 0.476 0.227 -0.933 0.933 0.000 1.000
0.206 0.240 0.057 -0.263 0.676 0.861 0.389
-2.00 -1.00 0.00 1.00 2.00
Favours opioid exposed ipre-school children Favours non-opioid exposed pre-school children
Figure 6 Forrest plots comparing psychomotor in opiod and non-opiod exposure.
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neurobehavioral tests at different ages of development.
Prenatal opioid exposure may affect children’s cognitive
and psychomotor performance differently at different
ages resulting in neurobehavioral outcomes that might
improve or worsen over time [5]. This analysis could
only be conducted during the two early stages of a
child’s development (infancy and pre-school children). It
was not possible to conduct a similar analysis on chil-
dren aged between 6–12 years due to the presence of
only one study meeting the criteria for analysis.
The studies included in the meta-analysis had differences
in the measurement of exposure to opiates. Most studies
involved the use of illicit heroin wherein the dosage is
highly variable and based on a large number of factors,
while two of the studies involved methadone prescribed in
a controlled environment. None of the studies commented
on the use of illicit drugs and alcohol which may also have
a bearing on the outcomes of interest.
Limitations
The results of our analysis must be cautiously interpreted
bearing its limitations in mind. The inclusion criteria used
for this meta-analysis was very stringent so as to exclude
neurobehavioral effects as a result of intra-uterine mater-
nal polydrug use and the potential confusion of neuro-
behavioral outcomes associated with the neonatal abstinent
syndrome and other opioid withdrawal presentations du-
ring the neonatal period (Jones et al., 2010). The main limi-
tation of using a meta-analytic technique is the small
number of primary studies available for analysis and also
their small sample size. This limits the generalisability of
the result [75] and the small sample size of individual stu-
dies means they may miss an increased risk of the occur-
rence of relatively rare outcomes like ADHD, autism or
psychosis. The quality assessment of the individual studies
would also raise some concerns about the generalisability
of the findings as all were reported as of moderate or
weak quality.
Meta-analysis tends to present results as composite
scores for broad neurobehavioral functions using different
neuropsychological tests. This is a convenient way to sum-
marise findings but it combines data from tests potentially
exploring different neuropsychological processes (e.g.
memory tests assessing immediate or delayed recall, lear-
ning or recognition) and possibly generating results of
questionable theoretical relevance. This study attempted
Study name Subgroup within study Outcome Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Hunt et al (2008) 3 years old Vineland Social maturity Scale (VSMS) 0.544 0.513 0.263 -0.461 1.548 1.061 0.289
Ornoy et al (2001/2003) 5 years old Achenbach Child Behavioural Checklist (CBCL)Externalis ing- Attention 0.442 0.574 0.330 -0.683 1.567 0.770 0.441
Walhord et al (2007) 4.5 years old Achenbach Child Behavioural Checklist (CBCL)Externalis ing-Attention 0.000 0.614 0.377 -1.204 1.204 0.000 1.000
0.359 0.325 0.105 -0.277 0.996 1.107 0.268
-2.00 -1.00 0.00 1.00 2.00
Favours opioid exposed pre-school children Favours non-opioid exposed pre-school children
Figure 7 Forrest plots comparing behaviour in opiod and non-opiod exposure.
Table 4 Effect sizes and associated statistics for neurobehavioral domains in opioid exposed infants and pre-school
children compared to others who have no history of opioid (or any other illicit and/or alcohol use) exposure during
pregnancy
Neuropsychological
Domains*
Studies1 Effect Size2 SE 3 N 4 Lower Limit 5 Upper Limit 6 Q 7 p for Q 8 Z 9 p for Z 10 I2 11 Fail safe
N 12
Infants
Cognition 4 0.24 0.17 251 −0.09 0.58 1.88 0.76 1.41 0.16 0.00 0
Psychomotor 4 0.28 0.17 251 −0.05 0.61 3.98 0.41 1.67 0.09 0.00 5
Behaviour*1 3 1.21 0.93 145 −0.61 3.03 7.13 0.03 1.30 0.19 71.93 2
Pre-school children
Cognition 3 0.18 0.25 224 −0.30 0.67 0.38 0.83 0.75 0.46 0.00 0
Psychomotor 3 0.28 0.28 224 −0.27 0.82 0.18 0.91 1.00 0.32 0.00 0
Behaviour 2 0.50 0.38 160 −0.25 1.25 0.02 0.89 1.30 0.19 0.00 np
1 = Number of studies used to calculate effect size, 2 = Cohen’s d effect size, 3 = Standard Error, 4 = Total number of subjects in opioid exposed cohort ,5 = Lower limit of
the 95% confidence interval for the effect size, 6 = Upper limit of the 95% confidence interval for the effect size, 7 = Q statistic: A test of homogeneity, 8 = Probability that
Q statistics significantly diff than 0, 9 = One sample Z Statistic, 10 = Probability that Z Statistics, is significantly diff than 0, 11 = I2 statistics, 12 = Fail Safe N: a measure of
publication bias, n/p = not possible since one needs more than 2 studies to perform this analysis, * All neuropsychological domains had random effects models
employed except*1 where random effect model employed.
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to minimise this by utilising neuropsychological domains
agreed by consensus and used in systematic reviews on
chronic substance use effects [24,76].
Even though the meta-analysis grouped together stu-
dies that used the same rating scales on a cohort who
clearly were exposed to opioids, it was not possible from
the information presented in the studies to exclude other
confounding effects such as dosage of maternal opioid
use during pregnancy [5], timing during pregnancy when
the fetus was exposed to opioids with potential resulting
behavioral teratogenicity [77], the differential effects of
exposure to different opioids [42] and/or gender specific
neurobehavioral influences [71], other illicit drugs in-
cluding cocaine and alcohol use during pregnancy [5].
Each included study reported that there were no poly-
drug using mothers within their cohorts but it is not
possible to be certain that this was achieved.
Clinical relevance
This meta-analysis helps in supporting certain clinical
observations in this population. The observed, if any, neu-
robehavioral outcomes in infants and pre-school children
prenatally exposed to opioids are very often attributed
to substance exposure. However it is important to exa-
mine the contribution of other influences on a child’s
development. Ongoing maternal depressive illness is cor-
related with poorer cognitive and motor development and
increase in teacher and parent rated behavior problems
in pre-school children [78,79]. Poverty and low socio-
economic status is inversely related to children’s developmen-
tal performance [80,81]. A study examining the relationship
between birth weight and cognitive functioning among
children in South Australia indicated that cognition at
2 years of age was significantly related to birth weight
[82]. However the magnitude of the association attenuated
over time became non-significant in childhood. Factors
that became significantly associated with neurobehavioral
outcomes included low socio-economic status, low mater-
nal IQ, poor quality of the home environment and child’s
lead exposure. Overall it is increasingly becoming evident
that the risk factors that can predict poor neurobehavioral
outcomes is not the drug fuelled lifestyle or actual sub-
stance exposure during pregnancy but the presence of
multiple, inter-related and weighted variables cumulatively
influencing neurobehavioral outcomes [3]. The risk factors
were: maternal mental health, maternal attitudes toward
parenting and maternal child–parent interaction, maternal
education, parental occupation, minority status, stressful
life events and family size with not one risk factor con-
tributing exclusively to one cognitive or other neuro-
behavioral outcomes.
In many countries, including the UK, pharmacological
maintenance with methadone is the first line of treat-
ment for pregnant opioid dependent women [17,83].
Whilst treatment with methadone during pregnancy re-
sults in fewer complications for both mother and infant
when compared with the use of illicit opioids such as
heroin, its use in pregnancy is associated with high rates
of neonatal abstinence syndrome [84,85]with its treat-
ment involving using another opioid, morphine [86].
Prenatal exposure to opioids also significantly increases
the risk of low birth weight and small head circumfe-
rence as shown in the cohort of children in the studies
selected for this review. However this analysis did not
observe any increased risk in neurobehavioral prob-
lems in opioid exposed infants and pre-school children
compared to non-exposed peers suggesting that there
is no neurobehavioral sequelae to the chronic prenatal
and, if treated for NAS with opioids, also postnatal, ex-
posure to opioids with any effects being short term
and/or reversible.
Conclusion
Chronic intra-uterine opioid exposed infants and pre-
school children experience no significant impairment
in neurobehavioral outcomes when compared to non-
exposed peers, although in all domains there was a trend
to poorer outcomes. Interpretation of this meta-analysis
needs to appreciate the heterogeneous population stu-
died, the limited number of studies analysed due to the
stringent inclusion criteria and the small numbers within
the individual studies. Additional studies are needed to
improve the power of a future meta-analysis to produce
significant results. And longitudinal studies are needed
to determine if any neuropsychological impairments ap-
pear after the age of 5 years and to help investigate fur-
ther the role of environmental risk factors on the effect
of ‘core’ phenotypes.
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